866-997-4948 (US-Canada Toll Free)

U.S. Vaccine Market - U.S. Industry Analysis, Size, Share, Growth, And Forecast, 2012 - 2018

Published By :

Transparency

Published Date : 2012-09-17

Category :

Pharmaceutical

No. of Pages : 71

Product Synopsis

This report helps to identify factors, which will be the driving force behind the U.S. vaccine market and sub-markets in the next six years. The report provides extensive analysis of the US vaccine industry, current market trends, industry drivers and challenges for better understanding of the U.S.vaccine market structure. The report has segregated the U.S. vaccine industry in terms of product type. Annual estimates and forecasts are provided for the period 2012 through 2018 in terms of in USD million. The report helps in providing a comprehensive overview for Market forces that are driving and restraining the growth of the industry Opportunities for the application segments  Up-to-date analysis of the latest trends in the industry  Acumen... Read More

Table Of Content

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 U.S. VACCINE MARKET, 2012 - 2018
3.1 MARKET OVERVIEW
3.2 VACCINE MARKET CHARACTERISTICS
3.3 LAWS AND REGULATIONS
3.3.1 VACCINE APPROVAL PROCESS
3.4 U.S. VACCINE MARKET ESTIMATE AND FORECAST, 2012 - 2018
3.4.1 MARKET SHARE BY VACCINE TYPE
3.5 LIST OF COMPANIES SUPPLYING VACCINES IN THE U.S.
3.6 VACCINE PRICING
3.6.1 PRICES FOR VACCINES CONTAINING THIMEROSAL AS A PRESERVATIVE
3.6.2 PRICES OF VACCINES FREE OF PRESERVATIVES:
3.7 MARKET DYNAMICS
3.7.1 DRIVERS
3.7.1.1 Rise in incidences of viral infection driving the growth of vaccine market in the U.S.
3.7.1.2 Biotechnology research enabling synthesis of new vaccines to target complex human diseases driving the vaccine market
3.7.1.3 Government recommendation for adult and adolescent immunization will boost the growth of Vaccine market in U.S.
3.7.1.4 Rise in infectious diseases in animals driving the market
3.7.2 RESTRAINTS
3.7.2.1 Cost of refrigeration
3.7.2.2 Short functional shelf life of certain vaccines will have negative impact on the market growth
3.7.3 OPPORTUNITIES
3.7.3.1 Huge product pipeline of the multinational firms will act as an opportunity for future growth
3.8 IMPACT ANALYSIS OF DRIVERS
3.9 IMPACT ANALYSIS OF RESTRAINTS
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 BARGAINING POWER OF SUPPLIER
3.10.2 BARGAINING POWER OF BUYER
3.10.3 RIVALRY AMONG EXISTING COMPETITORS
3.10.4 THREAT OF NEW ENTRANTS
3.10.5 THREAT OF SUBSTITUTE

CHAPTER 4 U.S. VACCINE MARKET BY PRODUCT TYPE
4.1 HUMAN VACCINE
4.1.1 MARKET ANALYSIS, SIZE AND FORECAST
4.1.2 MARKET ATTRACTIVENESS ANALYSIS FOR HUMAN VACCINE MARKET
4.1.3 PEDIATRIC VACCINES
4.1.3.1 Market Analysis, Size and Forecast
4.1.3.2 Pediatric vaccine price list
4.1.3.3 Pediatric Influenza Vaccine price list
4.1.3.4 HaemophilusInfluenzae Type B
4.1.3.4.1 Hib Pricing
4.1.3.5 Hepatitis A
4.1.3.5.1 HAV Pricing
4.1.3.6 Hepatitis B
4.1.3.6.1 Hepatitis B Pricing
4.1.4 ADULT & ADOLESCENT VACCINES
4.1.4.1 Market Analysis, Size and Forecast
4.1.4.2 Adult vaccine price list
4.1.4.3 Adult Influenza Vaccine price list
4.1.5 OTHER HUMAN VACCINES
4.1.5.1 Market Analysis, Size and Forecast
4.2 ANIMAL VACCINE
4.2.1 MARKET ANALYSIS, SIZE AND FORECAST
4.2.2 MARKET ATTRACTIVENESS ANALYSIS FOR ANIMAL VACCINE
4.2.3 LIVESTOCK VACCINES
4.2.3.1 Market Analysis, Size and Forecast
4.2.3.2 Bovine Vaccines
4.2.3.2.1 Market Analysis, Size and Forecast
4.2.3.3 Porcine Vaccines
4.2.3.3.1 Market Analysis, Size and Forecast
4.2.3.4 Ovine Vaccines
4.2.3.4.1 Market Analysis, Size and Forecast
4.2.4 COMPANION ANIMAL VACCINES
4.2.4.1 Market Analysis, Size and Forecast
4.2.4.2 Feline Vaccines
4.2.4.2.1 Market Analysis, Size and Forecast
4.2.4.3 Canine Vaccines
4.2.4.3.1 Market Analysis, Size and Forecast
4.2.4.4 Equine Vaccines
4.2.4.4.1 Market Analysis, Size and Forecast
4.2.5 OTHER ANIMAL VACCINES
4.2.5.1 Market Analysis, Size and Forecast

CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 MARKET SHARE ANALYSIS
5.2 COMPETITIVE ANALYSIS FOR KEY MARKET PLAYERS

CHAPTER 6 COMPANY PROFILE
6.1 SANOFI-AVENTIS
6.1.1 COMPANY OVERVIEW
6.1.2 FINANCIAL OVERVIEW
6.1.3 SWOT ANALYSIS
6.1.1 RECENT DEVELOPMENT
6.2 GLAXOSMITHKLINE
6.2.1 COMPANY OVERVIEW
6.2.2 FINANCIAL OVERVIEW:
6.2.3 SEGMENT OVERVIEW
6.2.4 SWOT ANALYSIS
6.2.5 RECENT DEVELOPMENTS
6.3 MERCK & COMPANY INCORPORATED
6.3.1 COMPANY OVERVIEW
6.3.2 FINANCIAL OVERVIEW:
6.3.1 RECENT DEVELOPMENT
6.4 PFIZER INCORPORATED
6.4.1 COMPANY OVERVIEW
6.4.2 FINANCIAL OVERVIEW
6.4.3 RECENT DEVELOPMENT
6.5 ASTRAZENECA PLC
6.5.1 COMPANY OVERVIEW
6.5.2 FINANCIAL OVERVIEW:
6.5.3 RECENT DEVELOPMENT
6.6 NOVARTIS AG
6.6.1 COMPANY OVERVIEW
6.6.2 FINANCIAL OVERVIEW:
6.6.3 SWOT ANALYSIS
6.6.1 RECENT DEVELOPMENT
6.7 BOEHRINGER
6.7.1 COMPANY OVERVIEW
6.7.2 NET SALES BY BUSINESS
6.7.3 SWOT ANALYSIS
6.7.4 RECENT DEVELOPMENT

List of Tables


TABLE 1 ACTS AND REGULATIONS PERTINENT TO VACCINE DEVELOPMENT 
TABLE 2 SELECT FDA AND ICH GUIDANCE DOCUMENTS RELEVANT TO VACCINE DEVELOPMENT 
TABLE 3 LOT-RELEASE TESTING GUIDLINES 
TABLE 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
TABLE 2 GSK PRODUCT PIPELINE 
TABLE 3 U.S. HUMAN VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 4 U.S. ANIMAL VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 5 U.S. LIVESTOCK VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018 (USD MILLION) 
TABLE 6 U.S. COMPANION ANIMAL VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012- 2018 (USD MILLION) 

List of Figures


FIG. 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD MILLION) 
FIG. 2 FDA REGULATORY REVIEW PROCESS 
FIG. 3 VACCINE APPROVAL PROCESS 
FIG. 4 U.S. VACCINE MARKET REVENUE, 2010 - 2018 (USD MILLION) 
FIG. 5 U.S. VACCINE MARKET SHARE, BY VACCINE TYPE 2012 ESTIMATE (%) 
FIG. 6 IMPACT ANALYSIS OF DRIVERS 
FIG. 7 PORTER’S FIVE FORCE ANALYSIS FOR U.S. VACCINE MARKET 
FIG. 8 U.S. HUMAN VACCINE MARKET REVENUE2010 - 2018(USD MILLION) 
FIG. 9 MARKET ATTRACTIVENESS ANALYSIS FOR U.S. HUMAN VACCINE MARKET 
FIG. 10 PEDIATRIC VACCINES MARKET REVENUE 2010 – 2018 (USD MILLION) 
FIG. 11 ADULT & ADOLESCENT VACCINESMARKETREVENUE 2010 - 2018(USD MILLION) 
FIG. 12 OTHER HUMAN VACCINESMARKETREVENUE2010 - 2018(USD MILLION) 
FIG. 13 U.S. ANIMAL VACCINEMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 14 MARKET ATTRACTIVENESS FOR U.S. ANIMAL VACCINE MARKET2012 
FIG. 15 LIVESTOCK VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 16 BOVINE VACCINES MARKETREVENUE 2010 - 2018 (USD MILLION) 
FIG. 17 PORCINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 18 OVINE VACCINES MARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 19 COMPANION ANIMAL VACCINESMARKETREVENUE2010 - 2018 (USD MILLION), 
FIG. 20 FELINE VACCINESMARKETREVENUE2010-2018 (USD MILLION) 
FIG. 21 CANINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 22 EQUINE VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 23 OTHER ANIMAL VACCINESMARKETREVENUE2010 - 2018 (USD MILLION) 
FIG. 24 MARKET SHARE OF MAJOR HUMAN VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 25 MARKET SHARE OF MAJOR ANIMAL VACCINE PRODUCERS IN THE U.S., 2011 (%) 
FIG. 26 GLOBAL VACCINE PLAYERS SALES GROWTH 2012-2018 
FIG. 27 SANOFI-AVENTIS, PERFORMANCE CHART (2009-2011) 
FIG. 28 SANOFI-AVENTIS, SWOT ANALYSIS 
FIG. 29 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010) 
FIG. 30 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2011 
FIG. 31 GLAXOSMITHKLINE PLC AG, SWOT ANALYSIS 
FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 33 MERCK, SWOT ANALYSIS 
FIG. 34 MERCK & CO. , PERFORMANCE CHART (2007-2011) 
FIG. 35 ASTRAZENECA PLC, MARKET SHARE BY SEGMENT IN 2011 
FIG. 36 ASTRAZENECA PLC, SWOT ANALYSIS 
FIG. 37 NOVARTIS AG, PERFORMANCE CHART (2007-2011) 
FIG. 38 NOVARTIS AG, SWOT ANALYSIS 
FIG. 39 BOEHRINGER, SWOT ANALYSIS 

Make an enquiry before buying this Report

Please fill the enquiry form below.

Full Name * Message
Your Email *
Job Title
Phone No. * (Pls. Affix Country Code) Security Code *

Upcoming Reports

  • Cardiac Assist Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    By - Transparency

    Cardiac Assist Devices (CAD) are type of mechanical pumps that work along with the heart to improve its pumping efficiency and maintain the optimum blood flow throughout the body. Cardiac Assist Devices can be segmented in three types ventricular assist devices, intra-aortic balloon pumps (IABPs) and total artificial heart. Ventricular assist device (VAD) is a mechanical pump which takes blood from a lower chamber of the heart and pumps it to the body and vital organs. Ventricular devices are of two types right ventricular assist device (RVAD), left ventricular assist device...

  • Air Care Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018

    By - Transparency

    Global market for air care is growing significantly due to the rising consumer concerns about aesthetic qualities of air care products and improving living standards. Despite of slower recovery rate from economic crisis, there is an increasing demand for air care products in the US market, as consumers are opting to purchase more expensive and aesthetically pleasing air care devices. Development of new range of air care products and packaging innovations are some of the important factors driving the growth of air care industry. However, economic influences, distribution issues, and...

  • Sulfur Chemicals Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019

    By - Transparency

    Sulfur has atomic number 16 and is represented with symbol “S”. Elemental sulphur is available as a crystalline bright yellow solid at room temperature. As sulfur is 0.0384% of the Earth’s crust, it is said to be the seventeenth abundant element. It has the ability to react either as a reducing agent or as an oxidant. Sulfur has the property to oxidize several nonmetals and metals that include carbon and leads to negative charge in large amount of the organosulfur compounds. It also reduces strong oxidants such as fluorine and oxygen. Sulfur is available in its pure...